Funds holding Vor BioPharma Inc
ISIN US9290332074 · United States
- Fund holders
- 33
- Of which ETFs
- 5 28 other funds
- Value held
- ≈ 74.9M $ 74.8M $ · 55.7K €
- Share of capital
- 7.5 % of 59.2M shares on Aug 6, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Select Biotechnology Portfolio Fidelity Select Portfolios | 1,536,125 | 23.7M $ | 0.44 % | 2.60 % | as of Feb 28, 2026 ↗ |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1,065,085 | 19M $ | 0.00 % | 1.80 % | as of Mar 31, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 932,400 | 16.6M $ | 0.22 % | 1.58 % | as of Mar 31, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 333,539 | 6M $ | 0.01 % | 0.56 % | as of Mar 31, 2026 ↗ |
| BlackRock Health Sciences Opportunities Portfolio BlackRock Funds | 115,078 | 1.8M $ | 0.03 % | 0.19 % | as of Feb 27, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 79,679 | 1.2M $ | 0.00 % | 0.13 % | as of Feb 28, 2026 ↗ |
| iShares Core S&P Total U.S. Stock Market ETF iShares Trust | 65,412 | 1.2M $ | 0.00 % | 0.11 % | as of Mar 31, 2026 ↗ |
| Direxion Daily S&P Biotech Bull 3X Shares Direxion Shares ETF Trust | 54,358 | 779K $ | 0.15 % | 0.09 % | as of Apr 30, 2026 ↗ |
| Simplify Propel Opportunities ETF Simplify Exchange Traded Funds | 53,510 | 954.6K $ | 1.38 % | 0.09 % | as of Mar 31, 2026 ↗ |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 33,131 | 511.5K $ | 0.00 % | 0.06 % | as of Feb 28, 2026 ↗ |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 26,581 | 410.4K $ | 0.00 % | 0.04 % | as of Feb 28, 2026 ↗ |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 24,151 | 372.9K $ | 0.00 % | 0.04 % | as of Feb 28, 2026 ↗ |
| Schwab Total Stock Market Index Fund SCHWAB CAPITAL TRUST | 22,204 | 318.2K $ | 0.00 % | 0.04 % | as of Apr 30, 2026 ↗ |
| VANGUARD BALANCED INDEX FUND VANGUARD VALLEY FORGE FUNDS | 18,770 | 334.9K $ | 0.00 % | 0.03 % | as of Mar 31, 2026 ↗ |
| BIOTECHNOLOGY ULTRASECTOR PROFUND ProFunds | 16,824 | 241.1K $ | 0.13 % | 0.03 % | as of Apr 30, 2026 ↗ |
| VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND VANGUARD INSTITUTIONAL INDEX FUNDS | 15,702 | 280.1K $ | 0.00 % | 0.03 % | as of Mar 31, 2026 ↗ |
| SIMT Small Cap Growth Fund SEI INSTITUTIONAL MANAGED TRUST | 13,216 | 235.8K $ | 0.09 % | 0.02 % | as of Mar 31, 2026 ↗ |
| Invesco RAFI US 1500 Small-Mid ETF Invesco Exchange-Traded Fund Trust | 9,152 | 131.1K $ | 0.00 % | 0.02 % | as of Apr 30, 2026 ↗ |
| Goldman Sachs Absolute Return Tracker Fund GOLDMAN SACHS TRUST | 9,093 | 162.2K $ | 0.00 % | 0.02 % | as of Mar 31, 2026 ↗ |
| Health Sciences Portfolio PACIFIC SELECT FUND | 6,863 | 122.4K $ | 0.03 % | 0.01 % | as of Mar 31, 2026 ↗ |
| T. Rowe Price Extended Equity Market Index Fund T. ROWE PRICE INDEX TRUST, INC. | 6,600 | 117.7K $ | 0.01 % | 0.01 % | as of Mar 31, 2026 ↗ |
| Ultra-Small Company Market Fund Bridgeway Funds, Inc. | 6,250 | 111.5K $ | 0.09 % | 0.01 % | as of Mar 31, 2026 ↗ |
| PROFUND VP BIOTECHNOLOGY ProFunds | 5,191 | 92.6K $ | 0.22 % | 0.01 % | as of Mar 31, 2026 ↗ |
| Large-Cap Growth Portfolio PACIFIC SELECT FUND | 2,905 | 51.8K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Victory Extended Market Index Fund Victory Portfolios III | 2,491 | 35.7K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Invesco Nasdaq Biotechnology ETF Invesco Exchange-Traded Fund Trust II | 960 | 14.8K $ | 0.02 % | 0.00 % | as of Feb 28, 2026 ↗ |
| ProShares Ultra Nasdaq Biotechnology ProShares Trust | 778 | 12K $ | 0.01 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Total Stock Market Index Trust John Hancock Variable Insurance Trust | 357 | 6.4K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| AVIP Fidelity Institutional AM Equity Growth Portfolio AuguStar Variable Insurance Products Fund Inc | 324 | 5.8K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Guardian Large Cap Fundamental Growth VIP Fund Guardian Variable Products Trust | 316 | 5.6K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| State Street Balanced Index Fund STATE STREET INSTITUTIONAL INVESTMENT TRUST | 291 | 5.2K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Knights of Columbus U.S. ALL CAP INDEX FUND ADVISORS' INNER CIRCLE III | 148 | 2.1K $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| VIFAG 2002, SICAV S.A. GESALCALA, S.A., S.G.I.I.C. | 55.7K € | 0.07 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table counts shares; this one measures what the company weighs inside each fund.
| Fund | Weight in fund | |
|---|---|---|
| Simplify Propel Opportunities ETF Simplify Exchange Traded Funds | 1.38 % | as of Mar 31, 2026 ↗ |
| Select Biotechnology Portfolio Fidelity Select Portfolios | 0.44 % | as of Feb 28, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 0.22 % | as of Mar 31, 2026 ↗ |
| PROFUND VP BIOTECHNOLOGY ProFunds | 0.22 % | as of Mar 31, 2026 ↗ |
| Direxion Daily S&P Biotech Bull 3X Shares Direxion Shares ETF Trust | 0.15 % | as of Apr 30, 2026 ↗ |
| BIOTECHNOLOGY ULTRASECTOR PROFUND ProFunds | 0.13 % | as of Apr 30, 2026 ↗ |
| Ultra-Small Company Market Fund Bridgeway Funds, Inc. | 0.09 % | as of Mar 31, 2026 ↗ |
| SIMT Small Cap Growth Fund SEI INSTITUTIONAL MANAGED TRUST | 0.09 % | as of Mar 31, 2026 ↗ |
| VIFAG 2002, SICAV S.A. GESALCALA, S.A., S.G.I.I.C. | 0.07 % | as of Dec 31, 2025 ↗ |
| Health Sciences Portfolio PACIFIC SELECT FUND | 0.03 % | as of Mar 31, 2026 ↗ |
Quarter after quarter
Each SEC quarterly data set, newest first. The change is read against the quarter before it.
| Quarter | Holders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 32 | +9 | 4,457,484 | +32.3 % |
| 2026Q1 | 23 | +11 | 3,370,344 | +2,841.3 % |
| 2025Q4 | 12 | 114,586 |
Institutional managers
77 managers declare this company to the SEC (Form 13F); the 25 largest follow.
| Manager | Shares | Value | |
|---|---|---|---|
| TCG Crossover Management, LLC | 5,673,078 | 96.5M $ | as of Mar 31, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 5,404,998 | 96.4M $ | as of Mar 31, 2026 |
| FCPM III SERVICES B.V. | 4,117,354 | 73.5M $ | as of Mar 31, 2026 |
| Venrock Adviser, LLC | 3,041,719 | 54.3M $ | as of Mar 31, 2026 |
| Frazier Life Sciences Management, L.P. | 2,543,939 | 45.4M $ | as of Mar 31, 2026 |
| Caligan Partners LP | 1,925,066 | 34.3M $ | as of Mar 31, 2026 |
| GREAT POINT PARTNERS LLC | 1,750,000 | 31.2M $ | as of Mar 31, 2026 |
| Paradigm Biocapital Advisors LP | 1,750,000 | 31.2M $ | as of Mar 31, 2026 |
| FMR LLC | 1,539,670 | 27.5M $ | as of Mar 31, 2026 |
| MARSHALL WACE, LLP | 1,153,276 | 20.6M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 1,118,458 | 20M $ | as of Mar 31, 2026 |
| NEXTBio Capital Management LP | 999,967 | 17.8M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 794,759 | 14.2M $ | as of Mar 31, 2026 |
| Logos Global Management LP | 750,000 | 13.4M $ | as of Mar 31, 2026 |
| Rosalind Advisors, Inc. | 700,000 | 12.5M $ | as of Mar 31, 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 555,702 | 9.9M $ | as of Mar 31, 2026 |
| UBS Group AG | 488,368 | 8.7M $ | as of Mar 31, 2026 |
| BRAIDWELL LP | 466,774 | 8.3M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 342,573 | 6.1M $ | as of Mar 31, 2026 |
| Clearline Capital LP | 326,168 | 5.8M $ | as of Mar 31, 2026 |
| SPHERA FUNDS MANAGEMENT LTD. | 321,917 | 5.7M $ | as of Mar 31, 2026 |
| Laurion Capital Management LP | 318,670 | 5.7M $ | as of Mar 31, 2026 |
| Propel Bio Management, LLC | 314,543 | 5.6M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 261,891 | 4.7M $ | as of Mar 31, 2026 |
| MILLENNIUM MANAGEMENT LLC | 258,587 | 4.6M $ | as of Mar 31, 2026 |
Declared shareholders of Vor BioPharma Inc
6 beneficial ownership filings. These stakes do not add up: an asset manager filing aggregates its own funds, already counted above.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| RA Capital Management, L.P. and 3 others | 19.90 % | 12,896,519 | as of Apr 20, 2026 · SCHEDULE 13D |
| TCG Crossover GP II, LLC and 4 others | 10.50 % | 5,673,078 | as of Mar 30, 2026 · SCHEDULE 13G |
| Venrock Healthcare Capital Partners III, L.P. and 6 others | 9.90 % | 5,083,877 | as of Mar 31, 2026 · SCHEDULE 13G |
| Verve Capital Limited | 9.30 % | 4,999,272 | as of Mar 31, 2026 · SCHEDULE 13G |
| FMR LLC and 1 other | 3.20 % | 1,539,670 | as of Mar 31, 2026 · SCHEDULE 13G |
| Qiming Venture Partners VIII-HC, L.P. and 3 others | 2.00 % | 1,089,767 | as of Mar 31, 2026 · SCHEDULE 13G |
Cite this page
Titelia. "Funds holding Vor BioPharma Inc". https://titelia.com/en/stocks/vor-biopharma-inc-US9290332074